Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:ALPA

ALPA LABORATORIES LTD

Healthcare › Pharmaceuticals & Biotechnology
₹50.80
at close · 30 Oct 2026
▼ 1.90 (-3.61%)

Latest filings

  1. Reg 74(5) certificate from registrar for Q2 FY27 filed · Compliance
  2. Alpa Labs 38th AGM: All 7 resolutions passed with over 99% majority · Compliance
  3. Alpa Labs 38th AGM: All 7 Resolutions Passed with Over 99% Majority · Compliance
All filings ↓
Ask Nexa about ALPA LABORATORIES LTD

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹111 Cr over the trailing twelve months.

Market Cap
₹107 Cr
P / E (TTM)
30.2×
EV / EBITDA
—
Div Yield
—
Growth
1.6%▲
Revenue 5y CAGR
PAT +14.3% · EBITDA -15.6%
Quality
13.6%▲
ROCE (5y median)
ROE 11.0% (5y median) · margin 3.1%
Leverage
0.01·
Debt / Equity · low
Net debt ₹1.87 Cr
Revenue FY21→FY26
1.1×▲
Margin +5.9 pts
₹98 Cr → ₹106 Cr
Cash conversion
0.24×▼
Operating cash ÷ profit · 5 yrs
₹19 Cr on ₹77 Cr
Moves on a normal day
1.20%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#81/160
P/B#9/163
ROCE#102/182
ROE#88/165
Debt / Equity#48/166
EBITDA margin#167/177
Revenue growth#58/161
Profit growth#145/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Profit compounding 14% a year over 5 years
Debt at 0.01× equity
lower than 72% of its 166 Pharmaceuticals peers
Concerns
Slow revenue growth — 2% a year over 5 years
Over 5 years it reported ₹77 Cr of profit and ₹19 Cr of operating cash — 0.24×
Less than 60p of every ₹1 of profit arrived as cash
Heavy working capital — 126 days of cash tied up

Charts

How has the market priced it — with filings on the timeline?

ALPA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from ALPA LABORATORIES LTD's filed financials and exchange disclosures

What does ALPA LABORATORIES LTD do?

ALPA LABORATORIES LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ALPA.

Is ALPA LABORATORIES LTD profitable?

Yes. Over the trailing twelve months ALPA LABORATORIES LTD reported a net profit of ₹3.49 Cr on revenue of ₹111 Cr.

Does ALPA LABORATORIES LTD pay a dividend?

Not in the latest reported year — ALPA LABORATORIES LTD's dividend payout for FY26 was nil.

Is ALPA LABORATORIES LTD debt-free?

No. It reported borrowings of ₹2.51 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹1.87 Cr after cash. Debt stands at 0.01× equity. That is lower than 72% of its 166 Pharmaceuticals peers.

Is ALPA LABORATORIES LTD expensive compared with its peers?

On trailing P/E, ALPA LABORATORIES LTD ranks 81 of 160 in Pharmaceuticals — cheaper than 50% of them, against an industry median of 29.9×. This is a position, not a valuation judgement.

How much does the ALPA LABORATORIES LTD share price move in a day?

On a typical session ALPA LABORATORIES LTD moves 1.20% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

Where can I track ALPA LABORATORIES LTD's announcements?

Every NSE and BSE filing by ALPA LABORATORIES LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.